Upadacitinib for the Treatment of Atopic Dermatitis in a Spanish Cohort-Real Life: Fifty-Two-Week Follow-up Results

Dermatitis. 2022 Nov-Dec;33(6S):S124-S127. doi: 10.1097/DER.0000000000000958. Epub 2022 Sep 21.

Authors

Jose-Juan Pereyra-Rodriguez, Pedro Herranz, Ignasi Figuras-Nart, Bibiana Perez, Marta Elosua, Monica Munera-Campos, Javier Melgosa-Ramos, Violeta Zaragoza Ninet, Juan Francisco Silvestre, Minia Campos-Domínguez, Antonio Guilabert, Javier Miquel, Sara Alcantara-Luna, Pablo de la Cueva, Esther Serra-Baldrich, Jose Carlos Armario-Hita

PMID: 36125777
DOI: 10.1097/DER.0000000000000958

No abstract available

MeSH terms

Cohort Studies
Dermatitis, Atopic* / drug therapy
Follow-Up Studies
Heterocyclic Compounds, 3-Ring
Humans
Treatment Outcome

Substances

upadacitinib
Heterocyclic Compounds, 3-Ring